Physiomics Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Peter Sargent

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	3.1yrs
Promedio de permanencia en la Junta Directiva	2.4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Peter Sargent (46 yo)

less than a year

Permanencia

Dr. Peter Joseph Sargent is Chief Operating Officer of Physiomics Plc from September 04, 2023 and serves as its Chief Executive Officer and Director from January 22, 2024. He joined Physiomics Plc in Septe...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Sargent	CEO, COO & Director	less than a year	sin datos	sin datos
David Fell	Co-Founder & Member of Scientific Advisory Board	no data	UK£2.63k	sin datos
Anthony Clayden	Head of Finance & Company Secretary	8.3yrs	sin datos	sin datos
Hayley Close	Head of Business Development	3.1yrs	sin datos	sin datos
Venkata Putcha	Head of Biostatistics	less than a year	sin datos	sin datos
Mark Middleton	Consultant & Member of Scientific Advisory Board	9.1yrs	sin datos	sin datos
Robert Jackson	Consultant & Member of Scientific Advisory Board	no data	sin datos	sin datos

3.1yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de RVW1 se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Sargent	CEO, COO & Director	less than a year	sin datos	sin datos
David Fell	Co-Founder & Member of Scientific Advisory Board	no data	UK£2.63k	sin datos
Mark Middleton	Consultant & Member of Scientific Advisory Board	9.1yrs	sin datos	sin datos
Robert Jackson	Consultant & Member of Scientific Advisory Board	no data	sin datos	sin datos
Shalabh Kumar	Independent Non-Executive Director	2yrs	UK£23.67k	sin datos
Timothy Corn	Independent Non-Executive Director	2.4yrs	UK£20.00k	sin datos
James Millen	Non-Executive Chairman	8.3yrs	UK£138.61k	0.93% £ 16.2k

2.4yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de RVW1 no se considera experimentada (2.2 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Physiomics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Dr. Christophe Chassagnole Step Down as Director and as Chief Scientific Officer of Physiomics plc

Less than half of directors are independent

Physiomics plc Announces Chief Executive Officer Changes

Physiomics Plc, Annual General Meeting, Nov 21, 2023

Physiomics Plc Appoints Dr Venkata Putcha, as Head of Biostatistics

Physiomics plc Appoints Dr. Peter Sargent as Chief Operating Officer

Recent updates

New major risk - Shareholder dilution

Dr. Christophe Chassagnole Step Down as Director and as Chief Scientific Officer of Physiomics plc

Physiomics Plc Increases Revenue Expectation for the Year 2025

First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.002 loss in 1H 2023)

New major risk - Financial position

Physiomics Plc to Report First Half, 2024 Results on Mar 07, 2024

New minor risk - Shareholder dilution

Less than half of directors are independent

Physiomics plc Announces Chief Executive Officer Changes

Physiomics Plc, Annual General Meeting, Nov 21, 2023

Physiomics Plc Appoints Dr Venkata Putcha, as Head of Biostatistics

Full year 2023 earnings released: UK£0.005 loss per share (vs UK£0.003 loss in FY 2022)

New minor risk - Financial data availability

Physiomics plc Appoints Dr. Peter Sargent as Chief Operating Officer

New minor risk - Shareholder dilution

First half 2023 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in 1H 2022)

Physiomics plc Announces Change of Job Title of Dr. Christophe Chassagnole from Chief Operating Officer to Chief Scientific Officer

Physiomics Plc Announces Successful Completion of its PARTNER Study

Full year 2022 earnings released: UK£0.003 loss per share (vs UK£0.002 loss in FY 2021)

Physiomics Plc, Annual General Meeting, Nov 22, 2022

Third quarter 2022 earnings released: UK£0.001 loss per share (vs UK£0.001 loss in 3Q 2021)

Physiomics Plc to Report Fiscal Year 2022 Results on Sep 29, 2022

Physiomics Plc Appoints Shalabh Kumar as Independent Non-Executive Director

Less than half of directors are independent

Physiomics plc Announces Board Changes, Effective April 1, 2022

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Physiomics Plc to Report First Half, 2022 Results on Mar 07, 2022

Physiomics plc Announces Board Changes

Full year 2021 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in FY 2020)

Physiomics plc Announces Earnings Guidance for the Year Ending June 30, 2021

First half 2021 earnings released: UK£0.001 loss per share (vs UK£0.001 loss in 1H 2020)

TRHC’s DoseMeRx Partners with Physiomics to Provide Precision Dosing for Oncology Medications

Physiomics Plc Announces Approval of NIHR-funded PARTNER Study

Annual earnings released: Revenue misses expectations

Full year earnings released - €0.00087 loss per share

Physiomics plc Receives Award from Bicycle Therapeutics plc and Merck KGaA to Further Contracts of Undisclosed Value for Projects

Full year earnings released - €0.00087 loss per share

Physiomics Plc to Report Fiscal Year 2020 Results on Sep 30, 2020

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad